MASH Treatment Market Set to Scale from $3.20 Billion to $19.81 Billion by 2035

MASH Treatment Market

The MASH Treatment Market was valued at $3.20 Billion in 2025 and is projected to reach $19.81 Billion by 2035, growing at a CAGR of 20.0 percent over 2026 to 2035, according to Strategic Revenue Insights. The first approved disease specific drugs for metabolic dysfunction associated steatohepatitis are the main reason, adding 7.5 percentage points to annual growth.

Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/mash-treatment-market

MASH Treatment Market Key Takeaways

  • The market grows 6.2x over ten years and passes $7.96 billion in 2030.
  • THR-beta agonists are the largest drug class with 52% of 2025 revenue, and GLP-1 receptor agonists follow at 28%.
  • Dual and triple agonists are the fastest growing drug class at 36.4% a year.
  • North America holds 55% of revenue, while Asia Pacific grows fastest at 23.6%.
  • Retail pharmacies lead distribution with 47%, and online pharmacies grow fastest at 25.6%.

What Is Driving Growth

Before approval, hepatologists could only advise weight loss and manage diabetes. Drugs such as Madrigal’s Rezdiffra, a THR-beta agonist, and Novo Nordisk’s Wegovy with a MASH label now give them a prescription aimed at the liver. In 2026 the UK MHRA authorised Rezdiffra on 3 June and conditionally approved Wegovy on 3 July, showing approvals moving beyond the US. After first approvals, the next drivers are the large undiagnosed patient pool (6.2 points), non-invasive tests replacing biopsy (4.8 points) and a pipeline of dual and FGF21 drugs (3.9 points). High drug cost and payer controls remove 2.6 points, and low diagnosis rates remove 1.8.

Segments, Regions and Key Players

By disease stage, F3 fibrosis holds 48% of 2025 revenue and F2 fibrosis 40%, while compensated cirrhosis holds 12% and grows fastest at 27.3%. North America leads with 55% and grows at 18.5%, Europe holds 23% at 20.0%, and Asia Pacific holds 15% but grows fastest at 23.6% as approvals and reimbursement spread.

Key companies include Madrigal Pharmaceuticals, Novo Nordisk, Eli Lilly, Akero Therapeutics, 89bio, Boehringer Ingelheim, Inventiva and Viking Therapeutics.

Frequently Asked Questions

How big is the MASH treatment market?

It is worth $3.20 billion in 2025 and is forecast to reach $19.81 billion by 2035, a 20.0% CAGR from 2026 to 2035.

Which drug class leads the market?

THR-beta agonists lead with 52% of 2025 revenue, while dual and triple agonists grow fastest at 36.4% a year.

What holds the market back?

High drug cost and payer controls, such as prior authorization and fibrosis stage rules, and low diagnosis rates in primary care slow how many patients start treatment.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com